{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:54:56Z","timestamp":1788893696970,"version":"build-2803163510"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to investigate human epidermal growth factor receptor 2 (HER2) protein expression and gene amplification status in uterine serous carcinoma (USC) and ovarian high-grade serous carcinoma (HGSC), determine the frequencies of HER2 overexpression\/amplification and HER2-low expression, evaluate two current HER2 interpretation criteria, and analyze the relationship between HER2 status and patient prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A total of 51 patients with USC (including eight cases of mixed endometrial adenocarcinoma with predominant serous carcinoma components) and 165 patients with ovarian HGSC (including 43 patients who received neoadjuvant chemotherapy) were retrospectively recruited from the Department of Pathology, Peking University People\u2019s Hospital between January 2019 and January 2025. Clinical and pathological characteristics were summarized. HER2 protein expression in whole-tissue sections was assessed using immunohistochemistry (IHC). HER2 scoring was performed according to two criteria: the 2023 American Society of Clinical Oncology\/College of American Pathologists HER2 Testing Guidelines in Breast Cancer and the HER2 Immunohistochemistry Scoring System for Endometrial Serous Carcinoma proposed by the International Society of Gynecological Pathologists (ISGyP). Fluorescence\n                      <jats:italic>in situ<\/jats:italic>\n                      hybridization (FISH) was subsequently performed on cases with IHC scores of 1+, 2+, or 3+ for validation. Survival analysis was conducted based on HER2 status.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HER2 gene amplification was detected in 15\/51 (29.4%) tissues from patients with USC (including mixed carcinomas with predominant serous morphology). HER2 amplification was identified in 6\/122 (4.9%) tissues from patients with primary ovarian HGSC without prior chemotherapy, and in 3\/43 (7.0%) tissues from patients with ovarian HGSC with residual disease after neoadjuvant chemotherapy. Evaluation of HER2 IHC results using both interpretation criteria revealed no difference in HER2 3+ expression rates for both USC and ovarian HGSC. However, differences existed in the classification of HER2-low expression (defined as IHC 2+ with negative FISH or IHC 1+). The ISGyP criteria identified more cases with low HER2 expression. For patients with USC, HER2 positivity was not statistically significantly associated with overall survival (OS) or progression-free survival (PFS), although it showed a trend toward higher recurrence. In terms of prognosis, for patients with ovarian HGSC group, HER2 positivity was associated with worse OS (p = 0.049). Among patients with ovarian HGSC after neoadjuvant chemotherapy, HER2 positivity was a strong predictor for shorter PFS (p = 0.003).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A certain proportion of USC and ovarian HGSC cases exhibit HER2 positivity and HER2-low expression. Different interpretation criteria lead to variations in the assessment of HER2 IHC results. The ISGyP criteria can identify more cases with low HER2 expression. Moreover, our findings suggest that HER2 status could be a relevant prognostic marker in these malignancies. Traditional anti-HER2 targeted therapies are indicated for HER2-positive patients, while a broader population of patients with HER2-low expression may benefit from novel anti-HER2 antibody-drug conjugates.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1618237","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:36:13Z","timestamp":1767681373000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Human epidermal growth factor receptor 2 expression in gynecologic serous carcinomas and preliminary analysis of its characteristics in patients post-neoadjuvant chemotherapy"],"prefix":"10.3389","volume":"15","author":[{"given":"Lili","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naixuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangzhou","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danhua","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2012-0416-RA","article-title":"HER2\/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges","volume":"138","author":"Buza","year":"2014","journal-title":"Arch Pathol Lab Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp058197","article-title":"The distinctive nature of HER2-positive breast cancers","volume":"353","author":"Burstein","year":"2005","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3892\/or.15.1.65","article-title":"Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer","volume":"15","author":"Yano","year":"2006","journal-title":"Oncol Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies - a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1997.4617","article-title":"Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women","volume":"65","author":"Matthews","year":"1997","journal-title":"Gynecol Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br J Cancer"},{"key":"B8","article-title":"Classification of tumours editorial board","volume-title":"World Health Organization Classification of Female Genital Tumours","year":"2020"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.4827","article-title":"HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients","volume":"24","author":"Morrison","year":"2006","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ygyno.2020.07.016","article-title":"Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: a multi-institutional cohort study","volume":"159","author":"Erickson","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0191972","DOI":"10.1371\/journal.pone.0191972","article-title":"The prognostic value of HER2 in ovarian cancer: a meta-analysis of observational studies","volume":"13","author":"Luo","year":"2018","journal-title":"PloS One"},{"key":"B13","doi-asserted-by":"publisher","first-page":"251","DOI":"10.3390\/curroncol32050251","article-title":"Molecular prognostic factors in uterine serous carcinomas: A systematic review","volume":"32","author":"Svarna","year":"2025","journal-title":"Curr Oncol"},{"key":"B14","article-title":"Overexpression of HER-2\/Neu in uterine serous papillary cancer","volume":"8","author":"Santin","year":"2002","journal-title":"Clin Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.11.154","article-title":"Her-2\/neu overexpression and amplification in uterine papillary serous carcinoma","volume":"22","author":"Slomovitz","year":"2004","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2012.02240.x","article-title":"Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma","volume":"103","author":"Togami","year":"2012","journal-title":"Cancer Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2020-0207-RA","article-title":"HER2 testing in endometrial serous carcinoma: time for standardized pathology practice to meet the clinical demand","volume":"145","author":"Buza","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2007.09.007","article-title":"An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study","volume":"108","author":"Grushko","year":"2008","journal-title":"Gynecol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/00004347-199904000-00007","article-title":"HER-2\/neu amplification and overexpression in endometrial carcinoma","volume":"18","author":"Rolitsky","year":"1999","journal-title":"Int J Gynecol Pathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21308","article-title":"Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma","volume":"104","author":"Santin","year":"2005","journal-title":"Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ygyno.2009.09.025","article-title":"Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study","volume":"116","author":"Fleming","year":"2010","journal-title":"Gynecol Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2009.03464.x","article-title":"HER-2\/neu receptor gene status in endometrial carcinomas: a tissue microarray study","volume":"56","author":"Xu","year":"2010","journal-title":"Histopathology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod Pathol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2016-0331-CP","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology","volume":"140","author":"Bartley","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0000000000000812","article-title":"HER2 protein overexpression and gene amplification in tubo-ovarian high-grade serous carcinomas","volume":"41","author":"Ersoy","year":"2022","journal-title":"Int J Gynecol Pathol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12916-025-03916-3","article-title":"A retrospective study evaluating the effect of trastuzumab addition to carboplatin\/paclitaxel on overall survival in patients with advanced-stage HER2\/neu-overexpressing uterine serous carcinoma or carcinosarcoma","volume":"23","author":"Lu","year":"2025","journal-title":"BMC Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3390\/cancers17071822","article-title":"Personalized treatment in ovarian cancer: a review of disease monitoring, biomarker expression, and targeted treatments for advanced, recurrent ovarian cancers","volume":"17","author":"Ettorre","year":"2025","journal-title":"Cancers"},{"key":"B29","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12032-017-0956-8","article-title":"Efficacy of neratinib in the treatment of HER2\/neu-amplified epithelial ovarian carcinoma in vitro and in vivo","volume":"34","author":"Menderes","year":"2017","journal-title":"Med Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/PGP.0000000000000302","article-title":"Pattern of HER-2 gene amplification and protein expression in benign, borderline, and Malignant ovarian serous and mucinous neoplasms","volume":"36","author":"Mohammed","year":"2017","journal-title":"Int J Gynecol Pathol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"101251","DOI":"10.1016\/j.gore.2023.101251","article-title":"Low-level expression of human epidermal growth factor receptor-2 (HER2) in high-grade mullerian tumors: implications for therapy decision making","volume":"49","author":"Abada","year":"2023","journal-title":"Gynecol Oncol Rep"},{"key":"B33","doi-asserted-by":"crossref","unstructured":"HER2 status as a potential predictive biomarker for ovarian clear cell carcinoma\n          \n          \n            \n              Bart\u016f\n              MK\n            \n            \n              N\u011bmejcov\u00e1\n              K\n            \n            \n              Mich\u00e1lkov\u00e1\n              R\n            \n            \n              Stru\u017einsk\u00e1\n              I\n            \n            \n              H\u00e1jkov\u00e1\n              N\n            \n            \n              Hojn\u00fd\n              J\n            \n          \n          10.1007\/s00428-023-03640-4\n          37676270\n          Virchows Arch\n          483\n          2023","DOI":"10.1007\/s00428-023-03640-4"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1618237\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T06:36:15Z","timestamp":1767681375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1618237\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":33,"alternative-id":["10.3389\/fonc.2025.1618237"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1618237","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"article-number":"1618237"}}